London-based Orthofuse has secured a £2.2 million seed round to reshape the way complex orthopaedic procedures are performed. The round was led by a group of angel investors, with additional participation from ACF Investors, Cambridge Angels, and Empirical Ventures.
With its seed funding, Orthofuse will advance its technical development, regulatory readiness, and strengthen partnerships as it prepares for early-stage clinical evaluations. In the next 12 months, “To develop an implant system with support from leading surgeons in the US.”
Reinvents orthopaedic surgery through smarter implants
Detailing the challenge that Orthofuse tackles, James Scott, CEO and Co-Founder of Orthofuse, told TFN, “The main pain point here is that orthopaedic trauma and spinal degenerative conditions are technically demanding, time-sensitive, and extremely challenging when there is poor bone quality. Current implant systems struggle to comprehensively meet the needs of the patient and the surgeon. The inherent limitations cause prolonged surgical times and increased risks to the patient.”
Orthofuse is developing a new generation of 3D-printed implant systems that introduce smarter architectures tailored to real surgical workflows. Using advanced additive manufacturing techniques, the company creates implants that reduce the number of steps required during insertion while maintaining strong fixation.
A key focus is improving reversibility, allowing surgeons to adjust or reposition hardware without compromising surrounding tissue. This shift is particularly valuable in complex trauma cases where anatomy can be unpredictable and small adjustments have a major impact.
By simplifying implant placement and reducing dependency on multi-step instrumentation, Orthofuse aims to shorten procedures, lower complication risks, and ultimately improve patient recovery trajectories.
Why are current implant systems holding surgeons back?
In high-pressure operating rooms, implant systems must deliver reliability and flexibility across a wide range of clinical scenarios. Existing tools often fall short. Once an implant is seated, attempts to adjust or reverse the placement can cause further tissue damage, an outcome surgeons aim to avoid in already difficult cases.
This limitation becomes even more pronounced during trauma surgery or complex spine procedures, where precision matters at every step. When tools are hard to manipulate, valuable minutes are lost. Longer surgeries are associated with increased infection risk, greater physical strain on surgeons, and slower patient recovery.
Orthofuse was created to address exactly this gap by tackling the need for systems designed not only for structural performance but also for manoeuvrability, reversibility, and surgical efficiency.
Beyond the product itself, Orthofuse is building systems that fit naturally into a surgeon’s workflow, with solutions designed around usability, predictability, and patient safety. Its approach combines engineering precision with a clear understanding of the realities of orthopaedic surgery.
James Scott, CEO and Co-Founder of Orthofuse: “Modern surgical practice demands implant systems that reflect the realities of the operating room. Orthofuse is developing a technology designed to simplify procedures, giving surgeons greater flexibility and confidence. This investment enables us to accelerate progress toward setting a new standard for safety and efficiency in orthopaedic care.”
Didier Cowling, Lead investor & Board Member: “Orthofuse has reimagined the fundamental architecture of implants to solve the inefficiencies of current solutions. We believe this approach has real value in improving orthopaedic care, and are pleased to support the team as they move forward.”
Tim Mills, Managing Partner, ACF Investors: “Orthofuse is tackling a critical challenge in surgery by coupling advanced engineering and clinical practicality. James and his team have developed a truly innovative approach to implant architecture that has the potential to significantly improve patient outcomes whilst enhancing surgical efficiency, and we are delighted to support them in this journey.”
